Abstract PURPOSE To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a molecule based on Eligen(®) technology), in osteoarthritis (OA) patients with moderate to severe knee pain and joint structural damage classified as Kellgren and Lawrence (KL)2-3. METHODS AND DESIGN This […]
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.
April 1, 2015
Osteoarthritis Cartilage